Frequently Asked Questions for PAR-13 -009 Secondary Dataset Analysis in Heart, Lung, and Blood Diseases and Sleep Disorders (R21)

Overview

The purpose of this funding opportunity is to stimulate well-focused secondary analyses using existing human datasets to test innovative hypotheses concerning the epidemiology, pathophysiology, prevention or treatment of diseases/conditions relevant to the NHLBI mission. The goal of this initiative is to support early-stage exploratory studies through analyses of existing datasets. This program will enable investigators to pursue innovative projects for which preliminary data are limited, and assist in demonstrating concept validity expected in NIH research project (R01) review.

Q: Are the applicants required to use only NHLBI datasets?
A: No, applicants may use data from a variety of sources, including, but not limited to, investigator-initiated research activities, cooperative agreements, and contracts from public or private sources, administrative data bases, and the NHLBI BioLINCC resource. In addition, datasets from industry-supported research and other non-NHLBI sources may be analyzed if they are considered to be relevant to the NHLBI mission and strategic plan.
http://www.nhlbi.nih.gov/about/org/mission.htm
http://www.nhlbi.nih.gov/about/strategicplan/index.htm

Q: How many receipt dates are there?
A: There is one annual submission date that occurs on October 21st. The last receipt date for the funding opportunity (FOA) is October 21, 2015. There are separate due dates for AIDS applications (generally on January 7th.)

Q: What IRG/Study section should I submit my grant application to?
A: This PAR will involve a Special Emphasis Panel convened by CSR. Applications will be evaluated for scientific and technical merit by this Special Emphasis Panel.

Q: Does this FOA support analysis of bio-specimens?
A: The FOA was primarily intended for analysis of existing datasets, as reflected by the allowable budget cap of $150,000 in Direct costs over the two year funding period. While this FOA does not explicitly prohibit analysis of biospecimens, the imposed budget caps may limit the ability to carry out these types of projects.

Q: Does early stage investigator status (ESI) apply to this announcement?
A: ESI status does not apply to R21 grants

Q: Does the PAR have set aside funds?
A: There are no set aside funds for this announcement. The applications will be percentiled and funded according to the current NHLBI pay line. Although funding decisions are usually made in priority score or percentile order, final funding decisions are based on considerations of program relevance, overlap with existing programs, availability of funds, and NHLBI Advisory Council recommendations.

Last update: November 2013

Skip footer links and go to content
Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon